Figure 5From: Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibitionIn vivo growth curves of seven patient-derived orthotopic xenografts of TNBC. Treatment with vehicle control in blue; doxorubicin in purple; rapamycin in red; CCI-779 in green. Tumor volumes in mm3. Each data point represents the mean tumor volume of each treatment group. Error bars represent standard error of the mean. CCI-779, temsirolimus; TNBC, triple-negative breast cancer.Back to article page